United Kingdom based, MRL was founded in 1997 and develops mycology (mushroom nutrition) and non-mycology products as dietary supplements or "functional foods".
MRL utilises proprietary Japanese production technology to cultivate selected strains of the different mushrooms in California. The strains have been selected for their overall bioactivity and for their stability (purity). The cultivation process is in accordance with the California Organic Food Act of 1990.
These mushroom nutrition products are not extracts, but instead contain both the mycelium and primordia (young fruitbody) of the mushroom cultivated into a biomass on an edible, sterile (autoclaved substrate). The cultivation process ensures that the biomass is free from contamination by other fungi or bacteria and that heavy metals (pesticides) are not present.
Following cultivation, the biomass is dried, powdered and tableted to food grade Good Manufacturing Practice (GMP) standards.
For more information, click here and download our brochure.
MRL Ltd. is commercializing mycological products that combine proprietary technology for mycological contaminate-free, cultivation to specific standards (conducted in California) along with patented extraction techniques to develop effective nutritional products. All MRL products are manufactured to food grade.
 |
|
Coriolus-MRL
Ingredients
Coriolus versicolor
|
Presentations
90 tablets x 500 mg - Bottle
250 gram powder tub with spoon
|
 |
 |
|
Cordyceps-MRL
Ingredients
Cordyceps sinensis
|
Presentations
90 tablets x 500 mg - Bottle
250 gram powder tub with spoon
|
|
 |
|
Reishi-MRL
Ingredients
Ganoderma lucidium
|
Presentations
90 tablets x 500 mg - Bottle
250 gram powder tub with spoon
|
|
 |
|
Maitake-MRL
Ingredients
Grifola frondosa
|
Presentations
90 tablets x 500 mg - Bottle
250 gram powder tub with spoon
|
|
 |
|
Triton-MRL
Ingredients
33% Ganoderma lucidium
33% Cordyceps sinensis
33% Lentinula edodes
|
Presentations
90 tablets x 500 mg - Bottle
250 gram powder tub with spoon
|
|
 |
|
Blazei-MRL
Ingredients
Agaricus blazei
|
Presentations
90 tablets x 500mg - Bottle
250 gram powder tub with spoon
|
|
 |
|
Auricularia-MRL
|
Presentations
250 gram presentation with 2 g spoon
|
|
 |
|
Pleurotus-MRL
|
Presentations
90 tablets x 500 mg-Bottle
250 gram presentation with 2 g spoon
|
|
 |
|
Polyporus-MRL
|
Presentations
90 tablets x 500 mg - Bottle
250 gram presentation with 2 g spoon
|
|
 |
|
Poria-MRL
|
Presentations
250 gram presentation with 2 g spoon
|
|
 |
|
Shiitake-MRL
|
Presentations
90 tablets x 500 mg - Bottle
250 gram presentation with 2 g spoon
|
|
 |
|
Hericium-MRL
|
Presentations
90 tablets x 500mg - Bottle
250 gram presentation with 2 g spoon
|
|
 |
|
Corpet-MRL
Ingredients
Coriolus versicolor - biomass powder
Microcrystalline Cellulose
Silica
Vegetable Magnesium Sterate
|
Presentations
90 tablets x 500mg - Bottle
750 gram powder tub with 10 gram spoon
|
The mycological products contain both mycelium and primordia (young fruit body). The proprietary technology used in the cultivation of MRL products ensures that the products are free from contamination by other fungi and that pesticides and heavy metals are absent.
In the Holland, the sterile powder is pressed into 500 mg tablets with a film coating which protects the powder from moisture. The production process is undertaken to food grade standards which ensures that each tablet has 500 mg of a standardised product.
In 1998, MRL formed an international Scientific Advisory Board (SAB) to advise MRL on all mushroom nutriton clinical development and basic research, both in the human and animal health areas.
The SAB members are:
|
|
|
Dr. Stefan Arver (MD, Ph.D)
Reproductive Medical Center
Karolinska Hospital
Stockholm, Sweden
|
|
Dr. Jan Bruhn (Ph.D)
Founder
Institute for Bioactive Natural Products
Uppsala, Sweden
|
|
Dr. Gosse Bruinsma (MD)
Vice President-Clinical Development
IntroGene Inc.
Leiden, Holland
|
|
Mr. Tom Chapman (Pharmacist)
Essential Nutrition Ltd.
Brough, United Kingdom
|
|
Mr. Malcolm Clark (MA)
Founder
Gourmet International
Sebastopol, California
|
|
Dr. Paul Greenhaff (Ph.D)
School of Biomedical Sciences
Medical School
Queen´s Medical Centre
University of Nottingham
Nottingham, United Kingdom
|
|
Mr. Christopher Hobbs (L.Ac.)
Hobbs Clinic
Oregon, United States
|
|
Dr. Abraham Kryger (DMD, MD)
Preventative Medicine Clinic of Monterey
California, United States
|
|
Professor Rudie Labadie (Ph.D)
(Retired)
Department of Pharmacognosy
University of Utrecht
Utrecht, Holland
|
|
Dr. Jose Rodriguez (MD)
(Retired)
Director of Research and Development
CEPA S.L.-Schwartz Pharma GmBh
Madrid, Spain
|
|
